AIMS: To study screening of high-risk individuals as part of a national diabetes prevention programme in primary health care settings in Finland between 2003 and 2007, and evaluate the cardiometabolic risk profile of persons identified for intervention. METHODS: High-risk individuals were identified by the Finnish Diabetes Risk Score (FINDRISC), history of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), cardiovascular disease (CVD), or gestational diabetes. Participants subsequently underwent an oral glucose tolerance test. CVD morbidity risk was estimated by the Framingham Study Risk Equation and CVD mortality risk by the Systematic Coronary Risk Evaluation Formula (SCORE). RESULTS: A high-risk cohort of 10,149 (of whom 30.3% men) was identified (mean age 54.7 for men, 53.0 for women). Altogether 18.8% of men and 11.5% of women had screen-detected diabetes. In total 68.1% of men and 49.4% of women had abnormal glucose tolerance (IFG, IGT or screen-detected diabetes). Furthermore, 43.2% and 41.5% of men, and 13.3% and 11.3% of women, respectively, had a high predicted risk of CVD morbidity or mortality. CONCLUSION: Prevalence of dysglycemia including undiagnosed diabetes and the predicted risk for CVD was alarmly high in the identified high-risk cohort, particularly in men.
AIMS: To study screening of high-risk individuals as part of a national diabetes prevention programme in primary health care settings in Finland between 2003 and 2007, and evaluate the cardiometabolic risk profile of persons identified for intervention. METHODS: High-risk individuals were identified by the Finnish Diabetes Risk Score (FINDRISC), history of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), cardiovascular disease (CVD), or gestational diabetes. Participants subsequently underwent an oral glucose tolerance test. CVD morbidity risk was estimated by the Framingham Study Risk Equation and CVD mortality risk by the Systematic Coronary Risk Evaluation Formula (SCORE). RESULTS: A high-risk cohort of 10,149 (of whom 30.3% men) was identified (mean age 54.7 for men, 53.0 for women). Altogether 18.8% of men and 11.5% of women had screen-detected diabetes. In total 68.1% of men and 49.4% of women had abnormal glucose tolerance (IFG, IGT or screen-detected diabetes). Furthermore, 43.2% and 41.5% of men, and 13.3% and 11.3% of women, respectively, had a high predicted risk of CVD morbidity or mortality. CONCLUSION: Prevalence of dysglycemia including undiagnosed diabetes and the predicted risk for CVD was alarmly high in the identified high-risk cohort, particularly in men.
Authors: Nina Rautio; Jari Jokelainen; Eeva Korpi-Hyövälti; Heikki Oksa; Timo Saaristo; Markku Peltonen; Leena Moilanen; Mauno Vanhala; Matti Uusitupa; Jaakko Tuomilehto; Sirkka Keinänen-Kiukaanniemi Journal: J Womens Health (Larchmt) Date: 2014-05-01 Impact factor: 2.681
Authors: Kati Vähäsarja; Sanna Salmela; Jari Villberg; Pauli Rintala; Mauno Vanhala; Timo Saaristo; Markku Peltonen; Sirkka Keinänen-Kiukaanniemi; Eeva Korpi-Hyövälti; Leena Moilanen; Leo Niskanen; Heikki Oksa; Marita E Poskiparta Journal: Int J Behav Med Date: 2014-02
Authors: Sanna M Salmela; Kati A Vähäsarja; Jari J Villberg; Mauno J Vanhala; Timo E Saaristo; Jaana Lindström; Heikki H Oksa; Eeva A-L Korpi-Hyövälti; Leena Moilanen; Sirkka Keinänen-Kiukaanniemi; Marita E Poskiparta Journal: Diabetes Care Date: 2011-12-21 Impact factor: 19.112
Authors: Urho M Kujala; Jari Jokelainen; Heikki Oksa; Timo Saaristo; Nina Rautio; Leena Moilanen; Eeva Korpi-Hyövälti; Juha Saltevo; Mauno Vanhala; Leo Niskanen; Markku Peltonen; Jaakko Tuomilehto; Matti Uusitupa; Sirkka Keinänen-Kiukaannemi Journal: BMJ Open Date: 2011-12-19 Impact factor: 2.692
Authors: Anne Jølle; Kristian Midthjell; Jostein Holmen; Jaakko Tuomilehto; Sven M Carlsen; Jonathan Shaw; Bjørn O Åsvold Journal: BMJ Open Diabetes Res Care Date: 2016-06-22
Authors: Luis A Valdez; Kristin E Morrill; Derek M Griffith; Nangel M Lindberg; Steven P Hooker; David O Garcia Journal: Am J Mens Health Date: 2019 Jan-Feb
Authors: Nina Rautio; Jari Jokelainen; Heikki Oksa; Timo Saaristo; Markku Peltonen; Mauno Vanhala; Hannu Puolijoki; Leena Moilanen; Jaakko Tuomilehto; Sirkka Keinänen-Kiukaanniemi; Matti Uusitupa Journal: BMJ Open Date: 2012-09-13 Impact factor: 2.692
Authors: Jennifer J Infanti; Fidelma P Dunne; Angela O'Dea; Paddy Gillespie; Irene Gibson; Liam G Glynn; Eoin Noctor; John Newell; Brian E McGuire Journal: Trials Date: 2013-05-02 Impact factor: 2.279
Authors: Angela O'Dea; Marie Tierney; Brian E McGuire; John Newell; Liam G Glynn; Irene Gibson; Eoin Noctor; Andrii Danyliv; Susan B Connolly; Fidelma P Dunne Journal: J Diabetes Res Date: 2015-08-18 Impact factor: 4.011